Voya Investment Management LLC lifted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 17.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,535 shares of the biopharmaceutical company’s stock after buying an additional 7,499 shares during the period. Voya Investment Management LLC’s holdings in Celldex Therapeutics were worth $125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after buying an additional 708,095 shares during the last quarter. State Street Corp boosted its stake in shares of Celldex Therapeutics by 4.7% in the 1st quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after buying an additional 202,375 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after buying an additional 219,661 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Celldex Therapeutics by 42.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares during the last quarter. Finally, TSP Capital Management Group LLC boosted its stake in shares of Celldex Therapeutics by 6.8% in the 2nd quarter. TSP Capital Management Group LLC now owns 1,135,748 shares of the biopharmaceutical company’s stock worth $2,805,000 after buying an additional 72,500 shares during the last quarter. Hedge funds and other institutional investors own 51.37% of the company’s stock.

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. ValuEngine downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $6.31.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at $2.89 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $4.55.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The company had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. During the same period last year, the firm earned ($0.29) EPS. Celldex Therapeutics’s revenue for the quarter was up 77.3% compared to the same quarter last year. equities research analysts anticipate that Celldex Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/voya-investment-management-llc-grows-stake-in-celldex-therapeutics-inc-cldx/1723010.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.